Valeo Pharma Inc VPHIF

Healthcare

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

GREY:VPHIF - Post by User

Valeo Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Jan 29, 2024 5:57pm

220 Views

Post# 35851503

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES

Record revenues of $54 million for fiscal 2023, up 94% over 2022
Revenues of $13.1 million for Q4-23, up 4% over Q4-22
Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up 80%
2023 adjusted EBITDA loss of $10.9 million compared to $14.5 million for 2022, down 25%
Total Enerzair and Atectura prescriptions for the 12 months ending October 31, 2023, exceeded 67,000, up 179% over October 31, 2022

MONTREAL, Jan. 29, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the fourth quarter and year-ended October 31, 2023.

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023 (newswire.ca)